Overview

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, prospective, randomized phase II trial designed to evaluate the efficacy and safety of short-course neoadjuvant chemoradiotherapy combined with the PD-1 monoclonal antibody serplulimab and the anti-angiogenic agent bevacizumab in patients with previously untreated pMMR/MSS middle and low locally advanced rectal cancer. The study plans to enroll a total of 200 participants (100 in the experimental arm and 100 in the control arm).

Phase:

PHASE2

Details

Lead Sponsor:

Changhai Hospital

Treatments:

Neoadjuvant Therapy